



(12) Translation of
European patent specification

(11) NO/EP 2925369 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 47/69 (2017.01)
A61K 9/08 (2006.01)
A61K 31/568 (2006.01)
A61K 31/57 (2006.01)
A61P 5/34 (2006.01)
A61P 15/08 (2006.01)

Norwegian Industrial Property Office

(21) Translation Published 2018.04.16

(80) Date of The European Patent Office Publication of the Granted Patent 2018.01.03

(86) European Application Nr. 13811121.6

(86) European Filing Date 2013.11.22

(87) The European Application's Publication Date 2015.10.07

(30) Priority 2012.11.28, IT, MI20122027

(84) Designated Contracting States: AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR

(73) Proprietor Altergon S.A., Via Dogana Vecchia 2, 6900 Lugano, CH-Sveits

(72) Inventor BERNAREGGI, Alberto, c/o Altergon S.A.Via Dogana Vecchia 2, CH-6900 Lugano, CH-Sveits
PUPPINI, Nadia, c/o Altergon S.A.Via Dogana Vecchia 2, CH-6900 Lugano, CH-Sveits
NENCIONI, Alessandro, c/o Altergon S.A.Via Dogana Vecchia 2, CH-6900 Lugano, CH-Sveits

(74) Agent or Attorney PROTECTOR INTELLECTUAL PROPERTY CONSULTANTS AS, Oscars gate 20, 0352 OSLO, Norge

(54) Title **AQUEOUS ORAL SOLUTIONS OF STEROID HORMONES AND HYDROXYPROPYL-BETA-CYCLODEXTRIN WITH OPTIMISED BIOAVAILABILITY**

(56) References Cited: SZENTE L ET AL: "Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL, vol. 36, 1 January 1999 (1999-01-01), pages 17-28, XP002231320, ISSN: 0169-409X, DOI: 10.1016/S0169-409X(98)00092-1, "BETA-HYDROXYPROPYL-CYCLODEXTRIN (ENCAPSIN (TM) REPLACEMENT) AVAILABLE THROUGH RDI DIVISION", INTERNET CITATION, October 2004 (2004-10), XP002362395, Retrieved from the Internet: URL:<http://www.researchd.com/janssen/410200.htm> [retrieved on 2006-01-06], US-A- 4 596

795, US-A1- 2006 008 420, PITHA J ET AL: "Effects of ethanol on formation of inclusion complexes of hydroxypropylcyclodextrins with testosterone or with methyl orange", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 80, no. 1-3, 25 February 1992 (1992-02-25), pages 243-251, XP025565701, ISSN: 0378-5173, DOI: 10.1016/0378-5173(92)90281-6 [retrieved on 1992-02-25], ZOPPETTI G ET AL: "Water soluble progesterone-hydroxypropyl-[beta]-cyclodextrin complex for injectable formulations", JOURNAL OF INCLUSION PHENOMENA AND MACROCYCLIC CHEMISTRY, KLUWER ACADEMIC PUBLISHERS, DO, vol. 57, no. 1-4, 28 February 2007 (2007-02-28), pages 283-288, XP019502865, ISSN: 1573-1111, DOI: 10.1007/S10847-006-9174-2 cited in the application, FINI ADAMO ET AL: "ATR/Raman and Fractal Characterization of HPBCD/Progesterone Complex Solid Particles", PHARMACEUTICAL RESEARCH (DORDRECHT), vol. 25, no. 9, September 2008 (2008-09), pages 2030-2040, XP019613160, ISSN: 0724-8741, DAHAN ARIK ET AL: "The Solubility-Permeability Interplay in Using Cyclodextrins as Pharmaceutical Solubilizers: Mechanistic Modeling and Application to Progesterone", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 99, no. 6, June 2010 (2010-06), pages 2739-2749, XP002701442,, US-A1-2006 058 262

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1.

Farmasøytisk sammensetning for bruk ved behandling, via oral administrering,
5 av lidelser som, krever administrering av progesteron eller testosteron, hvilken
sammensetning innbefatter et kompleks av hydroksypropyl- β -syklodekstrin
(HP β CD) med:

- progesteron (Prg), med molforhold HP β CD:Prg i området 1,7:1 til 2,4:1, eller

- testosteron (Tst), med et molforhold HP β CD: Tst i området 1,7:1 til 3,0:1;

10 hvor nevnte HP β CD inneholder mindre enn 0,3 masse-% usubstituert β -
syklodekstrin.

2.

Sammensetning for bruk i henhold til krav 1, hvor molforholdet mellom HP β CD
15 og Prg eller Tst er i området fra 2,0:1 til 2,2:1.

3.

Sammensetning for bruk i henhold til kravene 1-2, hvor molforholdet mellom
HP β CD og Prg eller Tst er 2:1.

20

4.

Sammensetning for bruk i henhold til kravene 1-3, i form av løsning.

5.

25 Sammensetning for bruk i henhold til krav 4, hvor konsentrasjonen av nevnte
Prg eller Tst er i området fra 5 til 100 mg/g av løsningen.

6.

Sammensetning for bruk i henhold til kravene 1-5, form av en løsning klar til
30 bruk, dispensert i enkelt-dose eller multidose-beholdere fremstilt av glass eller

plastmateriale.

7.

Sammensetning for bruk i henhold til krav kravene 1-6, **karakterisert ved at**
5 den er stabil ved romtemperatur i minst 24 måneder.